Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05292001 · ClinicalTrials.gov registry record · Phase 4

Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma

A Phase 4 study of Fracture and Acute Blood Loss Anemia, sponsored by Oregon Health and Science University.

Recruiting
Registry status
Phase 4
Development phase
150
Enrollment target
1
Study location

NCT05292001 is a Phase 4 study of Fracture and Acute Blood Loss Anemia that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 150 participants, below the 4,685-participant average among 9 other Fracture trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05292001, a Phase 4 study of Fracture and Acute Blood Loss Anemia, is actively recruiting participants, sponsored by Oregon Health and Science University.

RECRUITING
Registry status
Phase 4
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Acute blood loss in orthopaedic trauma and operative fracture care contributes substantially to perioperative anemia, which places participants at increased risk for complications including surgical site infection, cardiovascular complications, and even death. Anemia has further clinical implications in quality of life measures and is associated with fatigue, impaired physical performance, decreased exercise capacity, and mood disturbances. Thus, evaluation and treatment of perioperative anemia is critical in risk mitigation within orthopaedic surgery. The current standard of care for anemia is transfusion of packed red blood cells in only cases of severe anemia due to the substantial associated risks. A safer alternative is desirable because a critical number of participants do not meet the restrictive transfusion threshold and may suffer negative effects from anemia during recovery from the acute insult. The focus of this project is to pilot an investigation of the benefits of intravenous iron therapy (IVIT) in traumatically injured patients. Specifically, Aim I will determine feasibility of study design, recruitment, randomization, intervention implementation, blinded procedures, and retention. In Aim II, time to return to normal hemoglobin following traumatic orthopaedic injury will be assessed. With Aim III, the investigators will measure IVIT effect on participant-reported fatigue, physical function, and depression, and further determine if resolution of anemia is correlated to improvements in these measures in traumatically injured orthopaedic patients. Aim IV will focus on evaluating the role of IVIT on immune cells through a variety of novel laboratory assessments. The investigators expect this study to provide a better understanding of IVIT, which has the potential to alter providers' treatment approach of anemia in participants who sustain traumatic orthopaedic injury, thereby leading to decreased risks and improved recovery.

Interventions

  • OTHER Saline Placebo
  • DRUG Iron-Dextran Complex Injection [InFed]

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-06-01
Est. Completion 2026-05-31
Phase Phase 4

What the Registry Record Tells You About NCT05292001

The ClinicalTrials.gov registry entry for NCT05292001 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,685-participant average among 9 other Fracture trials with a reported enrollment target (97% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Fracture appearing as the primary indexed condition, and to 2 interventions - of which Saline Placebo is the first listed.

NCT05292001 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT05292001 about?

NCT05292001 is a clinical study titled "Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma". Acute blood loss in orthopaedic trauma and operative fracture care contributes substantially to perioperative anemia, which places participants at increased risk for complications including surgical site infection, cardiovascular complications, and even death. Anemia has further clinical implication...

What is the current status of trial NCT05292001?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2022-06-01. Estimated completion is 2026-05-31.

What conditions does trial NCT05292001 study?

This clinical trial studies the following conditions: Fracture, Acute Blood Loss Anemia.

What interventions are being tested in trial NCT05292001?

The interventions under investigation include: Saline Placebo (OTHER), Iron-Dextran Complex Injection [InFed] (DRUG).

Who is sponsoring clinical trial NCT05292001?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05292001 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fracture

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.